Discovery & Clinical Trials
News and Publications
Discovering, developing & commercializing broad-spectrum antivirals
Dedicated to preventing and treating life- threatening viral infections
Innovation to address high unmet medical needs
Welcome to Chimerix
(NASDAQ: CMRX) Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals in areas of high unmet medical need.
SUPPRESS Phase 3 Trial
SUPPRESS is designed to demonstrate the efficacy and safety of brincidofovir for the prevention of CMV infection versus a placebo control, as no therapy is currently approved for the prevention of CMV in HCT recipients.
Feb 27 2015
Chimerix to Announce Fourth Quarter and Year End 2014 Financial Results on March 6, 2015
Feb 26 2015
Chimerix Provides Update on Anticipated SUPPRESS Enrollment
Feb 25 2015
Chimerix to Present at the Cowen & Co. 35th Annual Health Care Conference